T-Cypher Bio
Company Details
Status: Private
Employees: 11-50
Location:
Oxford, United Kingdom
Type:
sample
Technology:
sample
sample
sample
sample
About: T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK.
We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies.
Our goals:
- Develop next generation TCR therapies for treatment of cancer and autoimmune disease
- Innovate to make TCR therapies widely available to patients
About T-Cypher
- Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder
- Proprietary disease target and TCR discovery platform
- Expanding TCR-bank against novel, differentiated targets
- Differentiated approach to multiplexing TCRs in therapeutic T-cells
- Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
T-Cypher Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.